More about our sector?

this is your place

Bigfinite and NNE Partnership

Bigfinite and NNE Partnership


San Francisco, California, July 9, 2019 — Bigfinite and NNE announced a strategic partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world’s leading pharmaceutical and biotech manufacturers.  

This collaborative effort is based on Bigfinite’s SaaS platform leveraging Industry 4.0 technologies like artificial intelligence (AI) and machine learning to improve manufacturing operations combined with NNE’s unique pharma domain expertise.  The Bigfinite platform will be able to successfully monitor and optimize NNE’s customer’s operations, identifying and eliminating the root causes of operational issues, enhancing operating performance – all while ensuring GxP compliance and inherent data integrity.  Members from both organizations will work side-by-side to combine NNE’s strong knowledge in pharma operation, automation, and regulations with Bigfinite’s big data, industry, and advanced technological experience.  

Pep, CEO of Bigfinite, said, “Partnering with NNE is a tremendous opportunity to accelerate the deployment of our platform and make ‘Pharma 4.0’ a reality.” 

While several of these digital technologies have been available for some time, the Pharmaceutical industry has moved slowly and cautiously into the digital world due to heavy regulations.  But as the pressure to reduce cost, raise quality, and the demand for personalized medicine increases, companies must evolve to changing requirements to stay ahead.       

Pharma manufacturers in the US alone wastes $50 billion each year and 70% of manufacturing data is never used.  This partnership will help improve those statistics – empowering pharma companies to see their fullest potential with the use of the Bigfinite platform and NNE’s expertise. 

According to Mogens Larsson, Vice President (VP), Automation & IT of NNE, “We are excited to partner with Bigfinite Inc., a joined effort to bring market-leading technology that is purpose-built for the industry to our customers, for real and impactful improvements on how to create value from manufacturing and GxP data.”


About NNE: NNE is an international company specialised in pharma engineering. We help pharmaceutical companies bring products to market by providing flexible, compliant and future-proof solutions. We have close to 1,000 professionals delivering global knowledge and best practices, all dedicated to supporting our customers globally and on local sites.

About Bigfinite Inc.: Bigfinite is a cloud-based SaaS platform for the Life Sciences Industry that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and IoT technologies.  Founded in 2014 by a veteran team that possesses over 30 years of expertise in Pharma and IT, Bigfinite offers an intuitive way to gain process and operational intelligence so you can improve manufacturing operations in a GxP compliant manner.  Our mission is to advance manufacturing operations so pharma and biotech companies can provide patients with the right medicine, at the right time, and at the right price.

Melissa Villalobos

Sales and Marketing Coordinator

Bigfinite Announces Additions to Executive Team

Bigfinite, Inc. (Bigfinite), the leading manufacturing data analytics platform company for regulated industries, today announced that Brian Sweeney, Lawrence Baisch and Glenn Griffin have been added to the leadership team.
Crystal Black VP of Marketing

AI Algorithm Qualification

Pharmaceuticals and Biotech companies have no doubt that Artificial Intelligence (AI) is here to stay. Nonetheless, the opportunities AI technology offers are developing at a slow pace in a rather conservative manufacturing industry, aimed at managing production risks under controls that are subject to strong regulations. Fear of change? Risk aversion? Likely not.
Jordi Guitart VP of Artificial Intelligence

Bigfinite Announces Senior Leadership Additions

Bigfinite, Inc. (Bigfinite), the leading manufacturing data analytics platform company for regulated industries, today announced that John Vitalie has been named Chief Executive Officer (CEO) and has been elected to the Board of Directors. David Merino has been named Chief Financial Officer (CFO) of Bigfinite.

Why Biotech and Pharma Need GxP for their Digital Transformation Projects Now

Technological Enhancements with Principal Component Analysis Combined with Artificial Intelligence

Bigfinite Closes Series B Financing with Atlantic Bridge and Honeywell Ventures to Drive Disruption in Manufacturing Analytics

2019 Xavier University AI Summit Reflections – Two Industries Ready for Change

Now that the dust has settled from the Xavier University AI Summit and our team is back to business, we’ve had time to process some of the highlights and key takeaways from the exciting event.  In the past few years, there has been a significant increase in the implementation of digital technologies into various industries that subsequently impacted the way we live, travel, and do business.  From driverless cars to 24/7 customer support chatbots, innovation and technology continue to spiral upward and as we’ve entered the 4th industrial revolution, and healthcare + biopharma should be no exception.  The Xavier University AI Summit is a great event that brings together a range of relevant stakeholders with common focus on artificial intelligence (AI).

Bigfinite and NNE Partnership

Bigfinite and NNE announced a strategic partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world's leading pharmaceutical and biotech manufacturers. 

Where are Pharma Companies in the Age of Artificial Intelligence?

They say good things come to those who wait; we say good things come to those who wait but only the things left by the visionaries before them.  The pharmaceutical industry has long been known to lag in the adoption of new technology due to strong regulations. Even though regulators have recently begun to open up to several new ‘big data’ or pharma 4.0 technologies - the question remains, if pharma companies are doing the same?  In 2016, the European Pharmacopoeia 9.0 in Chapter 5.21 announced that neural networks (NN) and support vector machines (SVM) are valid chemometric techniques for processing analytical data sets. 

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

Since the announcement of the 4th Industrial Revolution in 2011, multitudes of emerging technologies have transpired around “Industry 4.0”. Technologies such as digital twins, Industrial Internet of Things (IIoT), and cyber-physical systems have come into the scene as core elements, providing the necessary ingredients for a paradigm shift in manufacturing. Technologies around predictive analytics and artificial intelligence are pioneering new approaches with many use cases including predictive maintenance, autonomous process optimization, and pattern recognition - used to identify potential failures in real-time. Because of this, data science is becoming an invaluable discipline for our industry in order to transform information into knowledge.